Screening for Endometrial Microstructural Abnormalities Before IVF

Abstract

Endometrial microstructural abnormalities are increasingly recognized as significant contributors to implantation failure and suboptimal outcomes in in vitro fertilization (IVF). This review synthesizes the current scientific understanding of screening strategies for endometrial microstructural defects before IVF, integrating recent advances in diagnostic technology, pathophysiological insights, and guideline-based recommendations. We highlight the epidemiological burden, clinical implications, and evolving management paradigms, offering clinicians a comprehensive overview of evidence-based approaches for optimizing endometrial receptivity and improving assisted reproductive technology (ART) success rates.

Introduction

Successful implantation in IVF cycles requires a receptive endometrium, the integrity of which is contingent not only on gross morphology but also on the underlying microstructural environment. Microstructural abnormalities—encompassing glandular, stromal, and vascular alterations—are often subtle yet clinically significant contributors to unexplained infertility and recurrent implantation failure (RIF). Their detection prior to IVF is critical to maximize reproductive outcomes. This review aims to elucidate the scientific rationale, diagnostic modalities, and clinical management of endometrial microstructural abnormalities within the context of pre-IVF assessment, with emphasis on recent research and guideline-based practice.

Epidemiology / Disease Burden

The prevalence of endometrial microstructural abnormalities among women undergoing IVF is estimated to range from 10% to 30%, though precise figures are confounded by diagnostic variability. These abnormalities are disproportionately observed in cohorts with recurrent implantation failure, chronic endometritis, and unexplained infertility. Epidemiological studies suggest that up to 20% of women with multiple failed IVF cycles have underlying histopathological defects, underscoring the clinical impact of missed microstructural pathology on ART outcomes and the substantial burden on healthcare resources.

Pathophysiology

Endometrial receptivity is orchestrated by tightly regulated molecular, cellular, and vascular processes. Microstructural abnormalities may include altered gland-to-stroma ratios, stromal fibrosis, abnormal vascularization, and subtle inflammatory infiltrates. Disruptions in the expression of adhesion molecules (e.g., integrins), cytokines, and growth factors impair the endometrial window of implantation. Chronic subclinical inflammation, often associated with persistent bacterial colonization or immune dysregulation, may further compromise endometrial architecture, leading to impaired embryo apposition and invasion.

Risk Factors

Risk factors for endometrial microstructural abnormalities include a history of pelvic inflammatory disease, intrauterine procedures (e.g., curettage, myomectomy), chronic endometritis, endometriosis, and adenomyosis. Additional contributors encompass hormonal dysregulation (e.g., polycystic ovary syndrome), advanced maternal age, and repeated ART cycles. Genetic predispositions affecting endometrial repair or immune response have also been implicated in susceptibility to microstructural pathology.

Clinical Features

Clinical manifestations are often non-specific or asymptomatic, complicating timely detection. Some patients may report abnormal uterine bleeding, pelvic pain, or persistent vaginal discharge; however, the majority present solely with infertility or repeated ART failure. Subtle changes in endometrial thickness, abnormal vascular patterns on Doppler imaging, or persistently thin endometrium despite hormonal optimization may raise clinical suspicion for underlying microstructural defects.

Diagnosis

Diagnosis of endometrial microstructural abnormalities requires a multimodal approach. Transvaginal ultrasound, while useful for gross assessment, lacks sensitivity for subtle defects. Endometrial biopsy with histopathological analysis remains the gold standard, enabling identification of stromal edema, glandular atrophy, fibrosis, and inflammatory infiltrates. Advanced techniques, such as hysteroscopy, provide direct visualization and facilitate targeted sampling. Emerging modalities include high-resolution MRI, three-dimensional power Doppler imaging, and molecular profiling (e.g., endometrial receptivity array, ERA), which assess gene expression signatures and endometrial immune cell populations, offering functional insights into receptivity.

Treatment & Management

Management depends on the underlying abnormality. Chronic endometritis is treated with targeted antibiotic therapy, while fibrotic or glandular defects may necessitate hormonal modulation or surgical correction (e.g., hysteroscopic adhesiolysis). Immune-mediated abnormalities can benefit from immunomodulatory agents (e.g., corticosteroids, intralipid therapy). Optimization of endometrial thickness and vascularity through estrogen supplementation, low-dose aspirin, or pentoxifylline has shown promise in selected cases. Personalized treatment, guided by detailed histological and molecular assessment, is increasingly advocated to maximize the likelihood of implantation.

Recent Advances / Emerging Therapies

Technological innovations have transformed the landscape of endometrial assessment. The endometrial receptivity array (ERA) enables molecular timing of the implantation window, guiding personalized embryo transfer. Single-cell transcriptomics and spatial proteomics offer unprecedented resolution of endometrial cell populations and microenvironments. Stem cell therapy and regenerative strategies are being explored for refractory Asherman\"s syndrome and extensive fibrosis. Additionally, non-invasive biomarkers (e.g., uterine fluid cytokines, circulating microRNAs) are under investigation for early detection and monitoring of endometrial health pre-IVF.

Guideline Recommendations

Current guidelines from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) recommend targeted assessment of the endometrium in patients with recurrent implantation failure or unexplained infertility, prioritizing histopathological evaluation and hysteroscopy when indicated. Routine molecular screening is not yet universally endorsed but may be considered in select cases. Individualized, evidence-based management tailored to specific microstructural findings is encouraged to optimize reproductive outcomes.

Conclusion

Screening for endometrial microstructural abnormalities prior to IVF represents a critical step in the personalized management of infertility. Recent advances in diagnostic modalities and molecular profiling have enhanced our ability to detect and characterize these subtle yet clinically significant defects. Integration of guideline-based screening protocols and individualized treatment strategies promises to improve implantation rates, reduce the burden of ART failure, and ultimately enhance patient outcomes in assisted reproduction.